Failed Adoptive Immunotherapy with Tumor-Specific T Cells
Open Access
- 1 November 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (21) , 8062-8067
Abstract
Adoptive immunotherapy with tumor-specific T cells has emerged as a valid approach for prevention or treatment of diseases, such as melanoma and EBV-associated lymphoma. As interleukin (IL) 15 promotes survival of CD8+ memory CTLs, we hypothesized that it could be used to enhance antitumor immunity in vivo through the maintenance of adoptively transferred memory CTL. To test this, we treated mice bearing P1A+ tumors with adoptively transferred T cells possessing a transgenic Vα8+ T-cell receptor specific for the P1A tumor antigen (called P1CTL). Mice were then randomized to receive daily low-dose IL-15 (0.5 μg/day) or PBS. Mice receiving the transgenic P1CTL and IL-15 experienced a significantly delayed tumor relapse or complete tumor regression (P < 0.002 compared with PBS), with a striking persistence of the CD8+ Vα8+ P1CTL compared with mice receiving the CD8+ Vα8+ P1CTL and PBS vehicle (26.3 versus 5.1% P < 10−5). Animals exhibiting complete tumor regression had a significant population of CD8+ Vα8+ P1CTL (46%) that persisted with IL-15 treatment until 140 days after adoptive transfer and successfully defended them against tumor rechallenge without IL-15. Low-dose IL-2 afforded no protection over vehicle and resulted in lower percentages of T cells with an activated memory phenotype, lower Bcl-2 expression, and lower ex vivo antitumor cytotoxicity compared with mice treated with IL-15. Collectively, the data support the notion that exogenous low-dose IL-15 therapy can enhance and even reverse the limited efficacy of adoptively transferred tumor-specific T-cell therapy and may do so in a fashion that is superior and distinct from exogenous IL-2 therapy.Keywords
This publication has 34 references indexed in Scilit:
- Adoptive-cell-transfer therapy for the treatment of patients with cancerNature Reviews Cancer, 2003
- Lineage relationship and protective immunity of memory CD8 T cell subsetsNature Immunology, 2003
- Biochemical Mechanisms of IL-2–Regulated Fas-Mediated T Cell ApoptosisImmunity, 1998
- A potential role for interleukin-15 in the regulation of human natural killer cell survival.Journal of Clinical Investigation, 1997
- Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartmentImmunity, 1995
- Cloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 ReceptorScience, 1994
- Development and proliferation of lymphocytes in mice deficient for both interleukins‐2 and ‐4European Journal of Immunology, 1994
- High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findingsJAMA, 1986
- Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated LymphocytesAnnual Review of Immunology, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985